Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report
Open Access
- 1 January 2004
- journal article
- Published by Springer Nature in Biological Procedures Online
- Vol. 6 (1) , 144-148
- https://doi.org/10.1251/bpo83
Abstract
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance. Detection of mutations is helpful in clinical management of imatinib resistance. We established a very sensitive (ASO) PCR to detect mutations in an imatinib-resistant CML patient. Mutations C944T and T1052C were detected which cause complete partial imatinib resistance, respectively. This is the first report of multiple point mutations conferring primary imatinib resistance in same patient at the same time. Understanding the biological reasons of primary imatinib resistance is one of the emerging issues of pharmacogenomics and will be helpful in understanding primary resistance of molecularly-targeted cancer therapies. It will also be of great utilization in clinical management of imatinib resistance. Moreover, this ASO-PCR assay is very effective in detecting mutations related to imatinib resistance.Keywords
This publication has 54 references indexed in Scilit:
- Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levelsBlood, 2003
- Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon‐α regimens for early chronic phaseCancer, 2003
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibBlood, 2003
- Ergebnisse nach radioulnarer Arthrodese mit distaler Ellenteilresektion nach Kapandji-SauvéHandchirurgie Mikrochirurgie Plastische Chirurgie, 2003
- Cytogenetic and molecular mechanisms of resistance to imatinibSeminars in Hematology, 2003
- Mutations in the ABL kinase domain pre-exist the onset of imatinib treatmentSeminars in Hematology, 2003
- Molecular response to imatinib mesylate following relapse after allogeneic SCT for CMLBlood, 2003
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001